Instrument Inactif

Communiqués Cubist Pharmaceuticals Inc

Actions

US2296781071

Produits pharmaceutiques

Cours en clôture Nasdaq
- ^USD	-

09/12/14	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin	RE
08/12/14	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars	RE

Communiqués

13/01/15	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	BU
20/12/14	Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées	BU
20/12/14	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	BU
09/12/14	Cubist Pharmaceuticals : Ryan & Maniskas, LLP : Announces Investigation of Cubist Pharmaceuticals Inc.	PR
09/12/14	Cubist Pharmaceuticals : Comments on CUBICIN Patent Litigation	BU
08/12/14	CUBIST PHARMACEUTICALS : ALERT: Johnson & Weaver, LLP Investigates the Fairness of Price and Process in Proposed Sale of Cubist Pharmaceuticals, Inc. to Merck	BU
17/11/14	Cubist Pharmaceuticals : European Antibiotic Awareness Day Highlights Need for Urgent Action	PU
17/11/14	Cubist Pharmaceuticals : La journée européenne d’information sur les antibiotiques souligne le besoin d’une action urgente	BU
05/11/14	Cubist Pharmaceuticals : Names Dr. Patrick Vink Chief Operating Officer	BU
03/11/14	Cubist Pharmaceuticals : to Present at Jefferies 2014 Healthcare Conference	BU
21/10/14	Cubist Pharmaceuticals : Reports Third Quarter 2014 Financial Results	BU
21/10/14	Cubist Pharmaceuticals : Technical Data on Biotech Equities - Intrexon, Keryx Biopharma, Spectrum Pharma, Sangamo BioSciences, and Cubist Pharma	PR
20/10/14	Cubist Pharmaceuticals : Names Robert J. Perez Chief Executive Officer	BU
14/10/14	Cubist Pharmaceuticals : to Announce Third Quarter 2014 Financial Results on Tuesday, October 21, 2014	BU
08/10/14	Cubist Pharmaceuticals : to Present New Data from Study of fidaxomicin in Children with Clostridium Difficile-Associated Diarrhea at IDWeek 2014	BU
30/09/14	Cubist Pharmaceuticals : to Present New Data on Antibiotics Portfolio at IDWeek 2014	BU
18/09/14	Cubist Pharmaceuticals : annonce la poursuite de son expansion mondiale avec l'ouverture de son siège international à Zurich	BU
18/09/14	Cubist Pharmaceuticals : Announces Continued Global Expansion with Opening of International Headquarters in Zurich	BU
26/08/14	Cubist Pharmaceuticals : to Present New Data from Antibiotics Portfolio at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)	BU
25/08/14	Cubist Pharmaceuticals : to Present at Morgan Stanley Global Healthcare Conference	BU
22/08/14	Cubist Pharmaceuticals : annonce l’acceptation par l’EMA du dossier de demande d’autorisation de mise sur le marché du ceftolozane/tazobactam	BU
22/08/14	Cubist Pharmaceuticals : Announces EMA Acceptance of Ceftolozane/Tazobactam Marketing Authorization Application for Review	BU
08/08/14	Cubist Pharmaceuticals : Issues Voluntary Nationwide Recall of Nine Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Following Complaints of Foreign Particulate Matter in Reconstituted Vials	BU
06/08/14	Cubist Pharmaceuticals : Biotech Equities Roundup -- Keryx Biopharma, Vertex Pharma, NPS Pharma, Cubist Pharma, and Idera Pharma	PR
06/08/14	Cubist Pharmaceuticals : Issues Voluntary U.S. Recall of Certain Lots of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Due to Presence of Particulate Matter	BU